HUP0105302A2 - 2,3,4,5-Tetrahidro-1H-[1,4]benzodiazepin-3-hidroxámsavak mint mátrix metalloproteináz-inhibitorok, alkalmazásuk és eljárás az előállításukra - Google Patents
2,3,4,5-Tetrahidro-1H-[1,4]benzodiazepin-3-hidroxámsavak mint mátrix metalloproteináz-inhibitorok, alkalmazásuk és eljárás az előállításukraInfo
- Publication number
- HUP0105302A2 HUP0105302A2 HU0105302A HUP0105302A HUP0105302A2 HU P0105302 A2 HUP0105302 A2 HU P0105302A2 HU 0105302 A HU0105302 A HU 0105302A HU P0105302 A HUP0105302 A HU P0105302A HU P0105302 A2 HUP0105302 A2 HU P0105302A2
- Authority
- HU
- Hungary
- Prior art keywords
- benzodiazepine
- tetrahydro
- preparation
- hydroxamic acid
- matrix metalloproteinase
- Prior art date
Links
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 title 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 title 1
- YWCKAVNWINYYFA-UHFFFAOYSA-N n-hydroxy-2,3,4,5-tetrahydro-1h-1,4-benzodiazepine-3-carboxamide Chemical compound C1NC(C(=O)NO)CNC2=CC=CC=C21 YWCKAVNWINYYFA-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23908099A | 1999-01-27 | 1999-01-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0105302A2 true HUP0105302A2 (hu) | 2002-07-29 |
| HUP0105302A3 HUP0105302A3 (en) | 2002-09-30 |
Family
ID=22900512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0105302A HUP0105302A3 (en) | 1999-01-27 | 2000-01-27 | 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors, their use and process for their preparation |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1147095B1 (hu) |
| JP (1) | JP2002535392A (hu) |
| KR (1) | KR20010101730A (hu) |
| CN (1) | CN1197849C (hu) |
| AR (1) | AR022423A1 (hu) |
| AT (1) | ATE273288T1 (hu) |
| AU (1) | AU767039B2 (hu) |
| BG (1) | BG105736A (hu) |
| BR (1) | BR0007759A (hu) |
| CA (1) | CA2356267A1 (hu) |
| CZ (1) | CZ20012637A3 (hu) |
| DE (1) | DE60012883T2 (hu) |
| EA (1) | EA200100809A1 (hu) |
| ES (1) | ES2223470T3 (hu) |
| HU (1) | HUP0105302A3 (hu) |
| ID (1) | ID29046A (hu) |
| IL (1) | IL144168A0 (hu) |
| NO (1) | NO20013675L (hu) |
| NZ (1) | NZ511885A (hu) |
| PL (1) | PL349025A1 (hu) |
| PT (1) | PT1147095E (hu) |
| SK (1) | SK10422001A3 (hu) |
| TR (1) | TR200102131T2 (hu) |
| WO (1) | WO2000044730A1 (hu) |
| ZA (1) | ZA200104321B (hu) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2357110A1 (en) * | 2001-04-11 | 2002-10-11 | American Cyanamid Company | Method for the treatment of polycystic kidney disease |
| US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
| US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
| US6770647B2 (en) | 2001-08-17 | 2004-08-03 | Bristol-Myers Squibb Pharma Company | Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| BR0213736A (pt) | 2001-11-01 | 2004-10-19 | Wyeth Corp | ácidos hidroxâmicos de sulfonamida de arila alênica como metaloproteinase matriz e inibidores de tace |
| US7488754B2 (en) | 2002-04-05 | 2009-02-10 | Wyeth | Method for the treatment of polycystic kidney disease |
| BR0313459A (pt) * | 2002-08-13 | 2005-06-21 | Warner Lambert Co | Derivados monocìclicos como inibidores de metaloproteinases de matriz |
| AU2003304456A1 (en) | 2002-12-23 | 2005-03-16 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors |
| EP1625334B9 (en) | 2003-05-21 | 2012-07-25 | Alexza Pharmaceuticals, Inc. | Percussively ignited self-contained heating unit |
| JP5069108B2 (ja) * | 2004-07-21 | 2012-11-07 | メルク セローノ ソシエテ アノニム | オクタヒドロピロロ［２，３，ｃ］ピリジン誘導体と、その医薬としての利用法 |
| EP1865001A1 (en) * | 2006-06-08 | 2007-12-12 | Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh | Specific protease inhibitors and their use in cancer therapy |
| WO2007141029A1 (en) * | 2006-06-08 | 2007-12-13 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Specific protease inhibitors and their use in cancer therapy |
| US20080216828A1 (en) | 2007-03-09 | 2008-09-11 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
| FR2950057B1 (fr) | 2009-09-17 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
| FR2950056B1 (fr) | 2009-09-17 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
| ES2592154T3 (es) | 2010-07-08 | 2016-11-28 | Kaken Pharmaceutical Co., Ltd. | Derivado de N-hidroxiformamida y medicamento que contiene el mismo |
| WO2012036257A1 (ja) * | 2010-09-17 | 2012-03-22 | 国立大学法人東京大学 | 血小板の機能を維持するための組成物 |
| CN113194954A (zh) | 2018-10-04 | 2021-07-30 | 国家医疗保健研究所 | 用于治疗角皮病的egfr抑制剂 |
| CA3151199A1 (en) * | 2019-09-19 | 2021-03-25 | New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Stabilized c-fms intracellular fragments (ficd) promote osteoclast differentiation and arthritic bone erosion |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| JP3053222B2 (ja) * | 1995-04-20 | 2000-06-19 | ファイザー・インコーポレーテッド | Ｍｍｐおよびｔｎｆ抑制剤としてのアリールスルホニルヒドロキサム酸誘導体 |
| BR9611479B1 (pt) * | 1995-11-13 | 2009-01-13 | Ácidos alfa-iminoidroxÂmicos e carboxÍlicos n-substituÍdos cÍclicos e heterocÍclicos. | |
| US5753653A (en) * | 1995-12-08 | 1998-05-19 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| DK0874830T3 (da) * | 1995-12-08 | 2003-04-22 | Agouron Pharma | Metalloproteinaseinhibitor, farmaceutisk præparat indeholdende denne og den farmaceutiske anvendelse samt en fremgangsmåde til fremstilling deraf |
| NZ334252A (en) * | 1996-08-28 | 2000-11-24 | Procter & Gamble | Heterocyclic metalloprotease inhibitors |
| DK0923561T3 (da) * | 1996-08-28 | 2003-02-24 | Procter & Gamble | Heterocykliske metalloproteaseinhibitorer |
| TR199900383T2 (xx) * | 1996-08-28 | 1999-05-21 | The Procter & Gamble Company | 1,3-Diheterosiklik metaloproteaz inhibit�rleri. |
| CN1293663A (zh) * | 1998-01-27 | 2001-05-02 | 美国氰胺公司 | 为基质金属蛋白酶抑制剂的2,3,4,5－四氢－1h－[1,4]苯并二氮杂䓬－3－异羟肟酸 |
-
2000
- 2000-01-26 AR ARP000100323A patent/AR022423A1/es not_active Application Discontinuation
- 2000-01-27 TR TR2001/02131T patent/TR200102131T2/xx unknown
- 2000-01-27 BR BR0007759-3A patent/BR0007759A/pt not_active IP Right Cessation
- 2000-01-27 ES ES00909990T patent/ES2223470T3/es not_active Expired - Lifetime
- 2000-01-27 CZ CZ20012637A patent/CZ20012637A3/cs unknown
- 2000-01-27 IL IL14416800A patent/IL144168A0/xx unknown
- 2000-01-27 NZ NZ511885A patent/NZ511885A/xx unknown
- 2000-01-27 WO PCT/US2000/001991 patent/WO2000044730A1/en active IP Right Grant
- 2000-01-27 AU AU32160/00A patent/AU767039B2/en not_active Ceased
- 2000-01-27 PL PL00349025A patent/PL349025A1/xx not_active Application Discontinuation
- 2000-01-27 AT AT00909990T patent/ATE273288T1/de not_active IP Right Cessation
- 2000-01-27 HU HU0105302A patent/HUP0105302A3/hu unknown
- 2000-01-27 CN CNB008031355A patent/CN1197849C/zh not_active Expired - Fee Related
- 2000-01-27 CA CA002356267A patent/CA2356267A1/en not_active Abandoned
- 2000-01-27 KR KR1020017009430A patent/KR20010101730A/ko not_active Application Discontinuation
- 2000-01-27 PT PT00909990T patent/PT1147095E/pt unknown
- 2000-01-27 EA EA200100809A patent/EA200100809A1/ru unknown
- 2000-01-27 JP JP2000595986A patent/JP2002535392A/ja active Pending
- 2000-01-27 DE DE60012883T patent/DE60012883T2/de not_active Expired - Fee Related
- 2000-01-27 EP EP00909990A patent/EP1147095B1/en not_active Expired - Lifetime
- 2000-01-27 ID IDW00200101465A patent/ID29046A/id unknown
- 2000-01-27 SK SK1042-2001A patent/SK10422001A3/sk unknown
-
2001
- 2001-05-25 ZA ZA200104321A patent/ZA200104321B/en unknown
- 2001-07-26 NO NO20013675A patent/NO20013675L/no not_active Application Discontinuation
- 2001-07-26 BG BG105736A patent/BG105736A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TR200102131T2 (tr) | 2001-12-21 |
| SK10422001A3 (sk) | 2002-09-10 |
| BR0007759A (pt) | 2001-11-13 |
| ATE273288T1 (de) | 2004-08-15 |
| PT1147095E (pt) | 2004-12-31 |
| NZ511885A (en) | 2003-06-30 |
| HUP0105302A3 (en) | 2002-09-30 |
| CN1197849C (zh) | 2005-04-20 |
| AU767039B2 (en) | 2003-10-30 |
| EA200100809A1 (ru) | 2002-02-28 |
| IL144168A0 (en) | 2002-05-23 |
| WO2000044730A1 (en) | 2000-08-03 |
| KR20010101730A (ko) | 2001-11-14 |
| ES2223470T3 (es) | 2005-03-01 |
| CN1337952A (zh) | 2002-02-27 |
| DE60012883T2 (de) | 2005-08-25 |
| PL349025A1 (en) | 2002-07-01 |
| NO20013675D0 (no) | 2001-07-26 |
| EP1147095A1 (en) | 2001-10-24 |
| ID29046A (id) | 2001-07-26 |
| ZA200104321B (en) | 2002-08-26 |
| AR022423A1 (es) | 2002-09-04 |
| CA2356267A1 (en) | 2000-08-03 |
| AU3216000A (en) | 2000-08-18 |
| JP2002535392A (ja) | 2002-10-22 |
| EP1147095B1 (en) | 2004-08-11 |
| CZ20012637A3 (cs) | 2002-04-17 |
| BG105736A (en) | 2002-05-31 |
| NO20013675L (no) | 2001-09-21 |
| DE60012883D1 (de) | 2004-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0105302A3 (en) | 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors, their use and process for their preparation | |
| HUP0201633A3 (en) | Alpha-aminosulphonyl-acetohydroxamic acid derivatives with metalloprotease inhibiting effect, preparation and use thereof | |
| HUP0103376A3 (en) | New 3-aryl-2-hydroxypropionic acid derivative, pharmaceutical compositions containing it, process for their preparation and their use | |
| EG24169A (en) | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | |
| HUP0203669A3 (en) | Renin inhibitors, process for their preparation, pharmaceutical compositions containing them and their use | |
| HUP0200807A3 (en) | Substituted propionic acid derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
| ZA977700B (en) | Phosphinic acid amides as matrix metalloprotease inhibitors. | |
| HUP0102766A3 (en) | Aminomethylcarboxylic acid derivatives, their pharmaceutical use and pharmaceutical compositions comprising them | |
| AU4201799A (en) | Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors | |
| HK1045501A1 (zh) | 作為基質金屬蛋白酶抑制劑的異羥肟酸衍生物 | |
| IL147216A0 (en) | Arylsulfonamido-substituted hydroxamic acid derivatives | |
| IL129420A0 (en) | Substituted 4-biphenyl-4-hydroxybutyric acid derivatives as matrix metalloprotease inhibitors | |
| IL129035A0 (en) | 3-Mercaptoacetylamino-1,5-substituted-2-oxo- azepan derivatives useful as inhibitors of matrix metalloproteinase | |
| IL137162A0 (en) | 2,3,4,5-tetrahydro -1h- [1,4]-benzodiazepine -3- hydroxamic acids as matrix metalloproteinase inhibitors | |
| GB9916562D0 (en) | 3-Arylsulfonyl-2-(substituted-methyl) propanoic acid derivatives as matrix metalloproteinase inhibitora | |
| HRP970247B1 (en) | Substituted 4-arylbutric acid derivatives as matrix metalloprotease inhibitors | |
| GB9929979D0 (en) | Hydroxamic acid derivatives | |
| HUP0102447A3 (en) | Novel octahydro-6,10-dioxo-6h-pyridazino/1,2a//1,2/diazepin-1-carboxylic acid derivatives, preparation method and use for preparing therapeutically active compounds | |
| GB9917593D0 (en) | Compound, composition, process and use | |
| AU2002239438A1 (en) | 2,4-hexadienoic acid and derivatives as corrosion inhibitors | |
| HUP0004510A3 (en) | Process for obtaining l-dihydroorotic acid and use thereof | |
| AU7608100A (en) | 1-cyclohexene-1-carboxylic acid and 1-cyclohexene-1-carboxylates as neuraminidase inhibitors | |
| AU7268800A (en) | Active agent preparation for veterinary use and method for the production thereof | |
| AU2001252254A1 (en) | 2,6-diamino-6-methyl-heptanoic acid and derivatives, process for the preparationthereof and use thereof | |
| HUP0000982A2 (en) | Process for the preparation of 1,1-dioxo-penicillanic acid derivatives |